New advances in the treatment of Friedreich ataxia: promises and pitfalls
Wolfgang Nachbauer, Sylvia Boesch · Clinical Investigation · 2011
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Clinical Investigation · OMICS Publishing Group · article · 2011
Abstract
Friedreich ataxia (FRDA) is an autosomal recessive, neurodegenerative disease. It affects primarily the nervous system and the heart. Progressive gait and limb ataxia, dysarthria, loss of vibration and proprioceptive sense are characteristic neurological symptoms in FRDA. In approximately 96% of patients FRDA is caused by a triplet guanine-adenine-adenine expansion within the first intron of the FXN gene on chromosome 9q13. Increased numbers of guanine-adenine-adenine repeats are suggested to interfere with FXN transcription via heterochromatin-mediated silencing and result in frataxin deficiency in FRDA.
Genetic and biological studies support the role of frataxin as a multifunctional protein in iron-dependent mitochondrial pathways. Multicenter, randomized-controlled Phase III trials in FRDA failed to prove disease modifying properties of candidate substances until to date. Phase II studies attributed idebenone, a synthetic short chain quinine analogue of co-enzyme Q10, some clinical benefit. Recent Phas...
Open the resolved locator · 10.4155/cli.11.93
Metadata licence: OpenAlex metadata (CC0)